For years, the American pharmaceutical market has served as the global engine for drug discovery, effectively subsidizing lower prescription costs in Europe and elsewhere. Now, the Trump administration is attempting to tilt that seesaw. By forcing a dual-pronged strategy—simultaneously capping domestic prices while pressuring international allies to pay more—the White House is testing a high-stakes economic theory: that rebalancing the global cost burden will eventually yield a net increase in life-saving medical breakthroughs.
However, the transition is proving volatile. As drugmakers grapple with new "Most Favored Nation" (MFN) agreements, the industry is witnessing a shift in launch strategies, a standoff over pricing, and a complex calculus regarding the future of R&D.
The Chronology of a Policy Shift
The current administration’s campaign against high drug prices is one of the few policy areas where Donald Trump has successfully bridged the divide between his base and progressive Democrats. According to a March 2026 KFF poll, 72% of U.S. adults—including 77% of Democrats and 68% of Republicans—support stricter government regulation of prescription drug costs.
Trump’s initial attempt to implement MFN pricing during his first term was thwarted by federal courts, which blocked the move. Undeterred, the administration returned to the strategy in 2025. By September 2026, the White House announced it had successfully negotiated MFN agreements with 26 major pharmaceutical companies. These deals fundamentally tie the prices paid by U.S. federal programs, such as Medicaid, to the lower prices paid by wealthy foreign nations.
The administration’s strategy is explicitly two-sided: “We went way down and they went a little bit up,” Trump remarked during a September 18 White House announcement, referring to the downward pressure on U.S. costs and the upward pressure on European markets. When questioned on the mechanism for ensuring European compliance, the administration was blunt: if foreign nations refused to pay higher rates, the U.S. would leverage trade tariffs.
Shifting Launch Plans: The European Standoff
The pharmaceutical industry’s reaction to this pressure has been defensive. Faced with the prospect of "price referencing"—where a lower price in Europe could trigger a mandatory price reduction in the U.S.—drugmakers are changing their global strategy.
The result has been a measurable chilling effect on drug accessibility in Europe. According to data analyzed by Reuters from GlobalData, new drug launches in the EU fell by approximately 35% in the ten months following the May 2025 executive order, compared to the previous ten-month period.
Individual companies have begun to play hardball. Insmed, for instance, postponed the German launch of its lung disease medication, Brinsupri, in February, despite having secured European regulatory approval months prior. Others are choosing to bypass traditional discounting models entirely. Bristol Myers Squibb has stated its intention to launch its schizophrenia drug, Cobenfy, in the U.K. at a price point equivalent to its U.S. list price, with commercial leadership indicating a willingness to walk away from the market if U.K. health authorities refuse to recognize the drug’s value.
The U.S. Price Landscape: A Mixed Bag
While the MFN deals are designed to lower costs for the American taxpayer, they have not triggered a uniform drop in list prices. In fact, the pharmaceutical industry continues to raise list prices on existing products.
By mid-January 2026, data from 46brooklyn revealed that manufacturers had raised list prices on 872 brand-name drugs at a median rate of 4%. Notably, all 16 companies that had signed MFN deals by that time were among those that increased list prices on other products. However, the picture is not entirely bleak for the administration; there were 18 significant price decreases that, when weighted by gross Medicaid spending, outweighed the aggregate increases.
The strategy reached a new milestone in September 2026, when the White House announced that all 50 states would participate in a program designed to provide MFN pricing across all Medicaid programs, creating a massive, consolidated bargaining bloc.
Global Economic Implications
The pressure is beginning to move the needle internationally. Last December, the United Kingdom reached a strategic agreement to increase its investment in new medicines by 25%, a move partly achieved by raising the cost-effectiveness threshold used by the National Institute for Health and Care Excellence (NICE).
Economists are watching the impact on Japan and other markets closely. ING economists have warned that the MFN policy creates upward price pressure, which may discourage the local launch of new drugs as companies weigh the risk of reduced U.S. margins against the volatility of foreign pricing. The central question remains: if the revenue gained from higher foreign prices outweighs the revenue lost to U.S. price cuts, will the net increase in global capital lead to more R&D?
Does Revenue Drive Innovation? The Academic Debate
The theoretical foundation of the administration’s policy rests on the link between pharmaceutical revenue and medical innovation. Historical studies suggest this link is real, though complex.
A 2000 study by Duke economists Henry Grabowski and John Vernon found that expected returns and cash flow are primary determinants of R&D spending. When companies anticipate higher earnings, they are more likely to approve and fund high-risk, long-term research projects.
However, the response of innovation to revenue is not 1-to-1. A 2015 paper published in the RAND Journal of Economics by Pierre Dubois and colleagues calculated an elasticity of 0.23 for new chemical entities. In plain terms, this suggests that a 10% increase in expected revenue results in only a 2.3% increase in new drugs reaching the market. The authors noted that rising regulatory costs and the scientific difficulty of finding "low-hanging fruit" in drug discovery mean that output grows much more slowly than revenue.
The "Seasaw Math" Scenario
To understand the potential impact, we must look at the revenue distribution of new medicines. According to 2026 data from EFPIA, roughly 74% of revenue for new medicines comes from the U.S., while the five largest European markets account for about 15.6%.
- Scenario: If European revenue for new medicines rises by 25% (as suggested by the U.K. spending commitment), global revenue increases by roughly 3.9%.
- Innovation Gain: Applying the 0.23 elasticity estimate, this 3.9% revenue increase would theoretically yield a 0.9% increase in new chemical entities.
- The Bottom Line: On a baseline of 50 new drugs per year, this translates to roughly 0.45 additional drugs annually—or one additional breakthrough every two years.
This modest gain assumes that the U.S. price cuts do not exceed a 5.3% reduction in total revenue. If U.S. revenue drops by more than that to offset the European gains, the net effect on global innovation could turn negative.
The Long-Term Outlook
The Trump administration’s "Most Favored Nation" initiative represents the most aggressive attempt in decades to reshape the global pharmaceutical market. By treating drug pricing as a trade issue, the White House has effectively forced Europe to choose between higher costs or reduced access to the latest therapies.
However, the path forward is fraught with uncertainty. The "seesaw" math suggests that while there is potential for increased global revenue, the translation of that capital into tangible medical innovation is slow, inefficient, and dependent on a delicate balance of U.S. market stability. As drugmakers continue to delay launches and navigate the new regulatory reality, the global patient population remains caught in the middle of a grand economic experiment—one that promises more medicine in the long run, but risks higher costs and fewer options in the present.
Whether the administration’s pressure on international allies will ultimately act as a catalyst for a new golden age of drug discovery or simply create a fragmented, less accessible global market remains the defining question of the current healthcare policy era.
About the Author
